HypeCheck
← All Ingredients Joint Health

Boswellia

Also known as: Boswellia serrata, Indian frankincense, olibanum, AKBA, boswellic acids, Shallaki

Effective Dosage

300-500 mg daily based on study doses

What the Science Says

Boswellia is a gum resin extracted from Boswellia serrata trees, used for centuries in traditional medicine. Clinical trials show it reduces pain, stiffness, and swelling in osteoarthritis — including knee and hand OA — often within 2–4 weeks at doses of 300–500 mg daily. It also appears to lower inflammatory markers like IL-6, TNF-α, and CRP, and may support cartilage health by reducing breakdown enzymes and promoting collagen synthesis.

What It Doesn't Do

Not a proven cancer treatment — lab studies on cancer cells don't translate to human therapy. Won't regrow cartilage on its own. No solid evidence it improves memory or cognition independently. Not a replacement for prescribed medications in severe arthritis. The cognitive benefits seen in one pilot trial used a multi-ingredient blend, so Boswellia alone can't take credit.

Evidence-Based Benefits

Boswellia (often combined with turmeric/curcumin) demonstrates clinically meaningful reductions in joint pain, stiffness, and swelling in osteoarthritis patients, with one RCT showing significant pain relief in hand OA versus placebo (PMID: 40554037) and another showing reduced inflammatory biomarkers (IL-1, IL-6, TNF-α, hs-CRP) and cartilage degeneration markers in knee OA (PMID: 39875757). A 15-day RCT found a 98.5% reduction in posture-related low back pain with a turmeric-Boswellia formulation versus placebo (PMID: 39973246). Preliminary evidence also suggests potential benefits for cognitive function and sleep quality when combined with other botanicals (PMID: 41438191).

Moderate Evidence

Effective at: 300-500 mg daily based on study doses

Source: auto-research

Absorption & Bioavailability

Moderate — boswellic acids have limited absorption on their own; phytosome and lipid-based formulations (e.g., Casperome) are used in studies to improve uptake, but standard extracts still show clinical effects at 300–500 mg doses.

Red Flags to Watch For

  • Most positive trials use proprietary multi-ingredient blends (e.g., with turmeric/curcumin), making it hard to isolate Boswellia's individual contribution
  • Several studies are small (50–162 participants) and short-term (15–90 days); long-term safety data is limited
  • Lab-based anticancer findings are frequently misrepresented in marketing — no human cancer treatment evidence exists from the provided studies
  • Products vary widely in boswellic acid standardization; low-quality extracts may not deliver the doses used in trials
  • Some studies are industry-funded or use proprietary branded extracts, which may introduce bias

Research Sources

  • PubMed
  • NIH DSLD

This information is for educational purposes only and is not medical advice. Always consult a healthcare professional before starting any supplement regimen. Last updated: 2026-04-06